Ultragenyx Pharmaceuticals is a biotechnology company, focused on the identification, development, and commercialization of products that treat genetic diseases. The business focuses on treating ultra-rare and debilitating diseases. The company develops biologic candidates. One example of Ultragenyx’s products currently in clinical trials is KRN23, a human-monoclonal antibody that binds and reduces the biological activity of fibroblast growth factor 23 to enhance low phosphate levels in patients with either X-linked hypophosphatemia or tumor-induced osteomalacia. Additionally, the company produces products for fatty acid oxidation disorders and treatments for GNE myopathy. The company generates the vast majority of its revenue in the United States.